ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month
ImmunityBio confirmed its pivotal BCG-naive bladder cancer trial has adequate statistical power for a 2026 supplemental filing, but an FDA warning letter over misleading Anktiva promotional claims has
Separately, ANKTIVA secured regulatory approval in Macau SAR, marking the drug's first international market clearance and the beginning of ex-U.S. commercialization. But the bull case now runs directly into a regulatory wall: the FDA issued a warning letter over misleading promotional claims for ANKTIVA, triggering sharp selling — IBRX is down ~35.8% since last earnings. The stock has whipsawed as investors try to price positive clinical and international milestones against a concrete FDA enforcement action.
Watch for two things: the timeline on the supplemental filing to FDA in the BCG-naïve setting, and whether the warning letter escalates beyond a letter into further enforcement. The spread between those two outcomes defines the risk/reward from here.
ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month
NEW YORK, April 10 —
ImmunityBio's Anktiva bladder cancer trial cleared a key statistical hurdle, but an FDA warning letter just wiped $2bn off the stock.
- Q1 2026 net product revenue hit $44.2mn, up 168% YoY and 15% QoQ from $38.3mn in Q4 2025
- Stock at $7.34 with a negative 367x forward P/E. BTIG holds a Buy rating with a $13 price target, nearly double current levels
- Supplemental BLA submission for BCG-naive NMIBC on track for 2026. IDMC confirmed trial is adequately powered at N=366
What Actually Happened
Two things happened, and they contradict each other. First, the good news: the Independent Data Monitoring Committee reviewed interim complete response data on 183 evaluable patients in the QUILT-2.005 trial. The study compares Anktiva plus BCG versus BCG alone in BCG-naive bladder cancer patients. The IDMC confirmed the trial has enough statistical power to detect pre-specified differences. No additional enrollment is needed. The supplemental BLA remains on track for 2026, which would expand Anktiva's label beyond its current BCG-unresponsive approval into the much larger BCG-naive population.
Then came the blow. On March 13, the FDA's Office of Prescription Drug Promotion sent a warning letter calling ImmunityBio's promotional materials "false or misleading." The specific problem: a podcast featuring CEO Patrick Soon-Shiong in which he claimed Anktiva "can actually treat all cancers." The FDA said the materials "grossly misrepresent the benefits of Anktiva" — a drug approved for one specific type of bladder cancer. The stock fell 21% on March 24 when the letter went public. Securities class action lawsuits followed within days.
The Catch
The bull case treats this as a promotion compliance problem, not a product safety problem. BTIG kept its Buy rating and $13 target, calling it something that "can likely be resolved" based on historical precedent. Piper Sandler carries an Overweight rating and $12 target, projecting $195mn in 2026 Anktiva revenue. The company had $381mn in cash at quarter end, bolstered by $75mn in non-dilutive funding from Oberland.
The bear case is blunter: the CEO went on a podcast and told cancer patients his drug treats all cancers. That's not a paperwork error. It's the kind of statement that draws prolonged FDA scrutiny over every future promotional activity. With levered free cash flow still at negative $213mn over the trailing twelve months, ImmunityBio needs every quarter of clean commercial execution it can get. A company burning $200mn+ a year can't afford distractions from its own CEO.
Bottom Line
The trial data is strong. BCG-naive NMIBC is a bigger market than BCG-unresponsive, and clearing the statistical power check keeps the supplemental filing on schedule. But the FDA warning raises a question that has nothing to do with science and everything to do with whether management can stay out of its own way. What matters now is the FDA's response timeline — specifically, whether the warning escalates beyond a letter. If it stays at the promotion compliance level, the stock at $7.34 trades at a steep discount to $13 analyst targets. If it escalates, the lawsuits stop looking like ambulance-chasing and start looking like real liability.
For a deeper look at ImmunityBio's financials and valuation, generate a free Basis Report on IBRX.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
ImmunityBio confirmed statistical power in its pivotal randomized BCG-naïve NMIBC bladder cancer trial for ANKTIVA plus BCG vs. BCG alone, while simultaneously facing an FDA warning that puts its Anktiva hopes and valuation in focus.